David A. Siegel Acumen Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 469,100 shares of ABOS stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
469,100
Previous 392,100
19.64%
Holding current value
$1.08 Million
Previous $948,000
22.68%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ABOS
# of Institutions
78Shares Held
41.8MCall Options Held
57.7KPut Options Held
749K-
Ra Capital Management, L.P. Boston, MA14.9MShares$34.5 Million0.52% of portfolio
-
Franklin Resources Inc San Mateo, CA3.55MShares$8.2 Million0.0% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$7.89 Million4.37% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.3MShares$5.31 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$4.99 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $93.6M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...